<?xml version="1.0" encoding="UTF-8"?>
<ref id="B100">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Hung</surname>
    <given-names>I. F.-N.</given-names>
   </name>
   <name>
    <surname>Lung</surname>
    <given-names>K.-C.</given-names>
   </name>
   <name>
    <surname>Tso</surname>
    <given-names>E. Y.-K.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Chung</surname>
    <given-names>T. W.-H.</given-names>
   </name>
   <name>
    <surname>Chu</surname>
    <given-names>M.-Y.</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2020</year>). 
  <article-title>Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.</article-title>
  <source>
   <italic>Lancet Lond. Engl.</italic>
  </source>
  <volume>395</volume>
  <fpage>1695</fpage>â€“
  <lpage>1704</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S0140-6736(20)31042-4</pub-id>
 </mixed-citation>
</ref>
